Pharmacogenomics (PGx) has the potential to expedite the process of identifying effective antidepressants for patients with depression. To investigate the barriers and opportunities in the adoption of PGx testing, we conducted a survey of Internal Medicine, Psychiatry, and Neurology clinicians’ perceptions of PGx testing for antidepressants at Weill Cornell Medicine. We find while younger physicians are more likely to adopt PGx, more experienced clinicians and Psychiatry clinicians feel most well-informed about PGx testing for antidepressants.
Learning Objective: After participating in this session, the learner should be better able to:
1. Understand how to design and analyze electronic surveys to study the perceptions of clinicians on pharmacogenomics testing for antidepressants, and be able to discuss the difference across clinician specialties including Internal Medicine, Psychiatry, and Neurology.
Yiye Zhang (Presenter)
Weill Cornell Medical College, Cornell University
Yonaka Harris, NewYork City College of Technology
George Alexopoulos, Weill Cornell Medicine
Adam Stracher, Weill Cornell Medicine
Elizabeth Ross, Weill Cornell Medicine
Rainu Kaushal, Weill Cornell Medicine
Jyotishman Pathak, Weill Cornell Medical College, Cornell University